Want to see BMEA full AI Analyst Report?
Top Page
Biomea Fusion
(NASDAQ:BMEA)
Select Model
Select Model
Rating:42Neutral
Price Target:
$1.50
▼(-12.28% Downside)
Action:Reiterated
Date:09/26/26
The score is primarily constrained by weak financial performance (no revenue, ongoing losses, and persistent cash burn requiring external funding) alongside a technically bearish setup (price below major moving averages with negative momentum). Valuation contributes limited support because the company is unprofitable (negative P/E) and no dividend yield is available.
Positive Factors
Proprietary Drug Discovery Platform
Biomea’s proprietary covalent chemistry platform provides an internally developed foundation for discovering drug candidates. Its focus on selective and durable protein inhibition may support differentiated medicines and a repeatable pipeline beyond any single clinical program.
Negative Factors
No Commercial Revenue
Without product revenue, Biomea lacks a recurring commercial cash engine and must rely on successful clinical development before building durable operating income. This leaves financial performance highly dependent on pipeline progress rather than established customer demand.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary Drug Discovery Platform
Biomea’s proprietary covalent chemistry platform provides an internally developed foundation for discovering drug candidates. Its focus on selective and durable protein inhibition may support differentiated medicines and a repeatable pipeline beyond any single clinical program.
Read all positive factors
Biomea Fusion (BMEA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$92.05M
Dividend YieldN/A
Average Volume (3M)2.44M
Price to Earnings (P/E)―
Beta (1Y)1.75
Revenue GrowthN/A
EPS Growth83.55%
CountryUS
Employees37
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.50
Shares Outstanding72,483,850
10 Day Avg. Volume2,586,010
30 Day Avg. Volume2,442,088
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.19
Price to Sales (P/S)0.00
P/FCF Ratio-0.92
Enterprise Value/Market Cap0.78
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-774.77
Enterprise Value/Ebitda-2.11
Forecast
1Y Price Target
$6.80Price Target Upside297.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.81
Revenue Forecast (FY)N/A
Biomea Fusion Business Overview & Revenue Model
Company Description
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COV...
How the Company Makes Money
Biomea Fusion is a clinical-stage biotechnology company, and detailed, consistent operating revenue streams from product sales are not publicly evident because it does not have approved, commercialized drugs. As a result, the company’s ability to ...
Biomea Fusion Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
46
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -93.00K | -1.41M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -34.21M | -60.39M | -136.68M | -115.74M | -81.14M | -41.32M |
| Net Income | -32.54M | -61.80M | -138.43M | -117.25M | -81.83M | -41.57M |
Balance Sheet | ||||||
| Total Assets | 36.87M | 58.57M | 79.94M | 199.93M | 129.31M | 185.71M |
| Cash, Cash Equivalents and Short-Term Investments | 34.82M | 55.81M | 58.28M | 176.87M | 113.05M | 173.52M |
| Total Debt | 877.00K | 1.59M | 8.77M | 10.30M | 2.29M | 2.85M |
| Total Liabilities | 24.74M | 29.02M | 28.36M | 30.69M | 20.77M | 6.92M |
| Stockholders Equity | 12.14M | 29.55M | 51.57M | 169.24M | 108.54M | 178.78M |
Cash Flow | ||||||
| Free Cash Flow | -47.06M | -70.37M | -120.26M | -99.96M | -63.45M | -38.61M |
| Operating Cash Flow | -47.06M | -70.37M | -119.89M | -96.59M | -62.42M | -35.44M |
| Investing Cash Flow | 550.00K | 0.00 | -362.00K | -2.22M | 27.34M | -33.35M |
| Financing Cash Flow | 25.11M | 67.90M | 1.67M | 163.80M | 1.24M | 153.19M |
Biomea Fusion Technical Analysis
Negative
1.71
Price Trends
1.50
Negative
1.40
Negative
1.42
Negative
Market Momentum
-0.09
Positive
35.39
Neutral
7.96
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BMEA, the sentiment is Negative. The current price of 1.71 is above the 20-day moving average (MA) of 1.61, above the 50-day MA of 1.50, and above the 200-day MA of 1.42, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 35.39 is Neutral, neither overbought nor oversold. The STOCH value of 7.96 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BMEA.
Biomea Fusion Risk Analysis
Biomea Fusion disclosed 91 risk factors in its most recent earnings report. Biomea Fusion reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Biomea Fusion Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $377.55M | 3.08 | -38.12% | ― | 30.47% | ― | |
53 Neutral | $464.81M | -4.96 | -23.64% | ― | -76.20% | 52.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $124.59M | -1.84 | -27.23% | ― | -13.23% | 12.29% | |
44 Neutral | $119.94M | -1.00 | -1005.80% | 0.36% | -100.00% | 54.89% | |
43 Neutral | $23.35M | -0.54 | -102.99% | ― | ― | -28.83% | |
42 Neutral | $92.05M | -2.56 | -171.19% | ― | ― | 83.55% |
* Healthcare Sector Average
BMEA
Biomea Fusion
1.27
-1.40
-52.43%
AGEN
Agenus
8.36
4.21
101.45%
INO
Inovio Pharmaceuticals
1.16
-1.25
-51.87%
ATOS
Atossa Therapeutics
2.34
-12.66
-84.40%
OVID
Ovid Therapeutics
2.38
0.59
32.96%
SEER
Seer
2.25
>-0.01
-0.44%
Biomea Fusion Corporate Events
Business Operations and StrategyProduct-Related Announcements
Biomea Fusion Updates Timeline for BMF-650 Phase I Data
Neutral
Sep 22, 2026
On September 22, 2026, Biomea Fusion, Inc. reported an updated timeline for topline results from its ongoing Phase I GLP-131 clinical trial of BMF-650, conducted in obese but otherwise healthy volunteers. The company now expects to release these i...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.